GleamWall
中文EN

CAI Caris Life Sciences, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2019410 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY61.5%
TTM net income YoY151.4%
TTM EPS YoY125.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin13.4%
Net margin9.2%
FCF margin2.8%
EBITDA margin15.5%

Returns

ROE17.2%
ROA8.6%
ROIC (approx.)24.3%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets49.1%
Debt / equity0.61x
Current ratio6.71x
Interest coverage3.28x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio1.1%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$275.36M$263.71M$216.17M$292.89M$216.83M$181.40M$120.92M$129.91M
R&D expense$33.84M$32.36M$31.32M$31.84M$21.62M$25.05M$23.07M$27.11M
SG&A expense$69.28M$66.55M$59.71M$56.51M$51.97M$64.37M$52.12M$43.11M
Operating income$19.32M$26.93M$5.28M$88.41M$32.64M-$17.99M-$57.95M-$37.05M
Interest expense$9.25M$9.23M$12.81M$11.36M$13.51M$19.21M$12.78M$13.26M
Pretax income$16.87M-$614,000-$644,000$81.96M$24.32M-$71.79M-$102.58M-$36.95M
Income tax$1.62M$23,000-$134,000$0$0$0$0$0
Net income$15.25M-$637,000-$510,000$81.96M$24.32M-$71.79M-$102.58M-$36.95M
EBITDA$25.92M$33.43M$10.35M$92.70M$37.54M-$11.59M-$50.91M-$27.98M
EPS (basic)0.050.000.00—0.09-7.97-3.57—
EPS (diluted)0.050.000.00—0.08-7.97-3.57—
Weighted avg. shares (diluted)295.14M282.89M282.56M—297.21M64.92M35.62M—
Balance sheet
Cash & equivalents——$819.90M$796.27M$753.22M$718.93M$31.20M$63.95M
Short-term investments$102.06M$102.20M$2.31M$2.29M$2.27M$2.25M—$2.20M
Receivables$133.32M$116.89M$90.52M$112.14M$26.70M$50.89M—$88.24M
Current assets$1.07B$1.06B$1.01B$997.80M$854.25M$833.32M—$215.73M
PP&E, net$102.30M$95.72M$82.67M$63.17M$64.00M$61.31M—$67.82M
Goodwill$19.34M$19.34M$19.34M$19.34M$19.34M$19.34M—$19.34M
Total assets$1.26B$1.23B$1.16B$1.13B$984.57M$955.06M—$343.73M
Current liabilities$158.95M$191.44M$143.90M$127.14M$86.03M$90.18M—$165.42M
Short-term debt$89,000$178,000$173,000$169,000$164,000$95,000—$60.09M
Long-term debt$393.18M$392.97M$381.40M$378.82M$376.30M$373.61M—$319.44M
Total debt$393.27M$393.15M$381.57M$378.99M$376.46M$373.71M—$379.53M
Total liabilities$616.14M$637.89M$568.90M$548.36M$506.21M$502.15M—$620.92M
Shareholders' equity$639.48M$591.73M$593.49M$577.31M$478.36M$452.90M-$2.60B-$2.50B
Net debt——-$438.33M-$417.28M-$376.76M-$345.23M—$315.58M
Shares outstanding286.72M282.58M282.65M282.53M282.10M281.09M—36.50M
Cash flow statement
Operating cash flow-$22.25M$28.48M$32.88M$44.78M$62.42M$7.29M-$31.34M-$38.92M
Capital expenditure$17.47M$22.07M$10.34M$5.09M$7.09M$1.39M$2.69M$2.29M
Free cash flow-$39.72M$6.40M$22.53M$39.69M$55.33M$5.90M-$34.03M-$41.21M
Investing cash flow-$17.47M-$122.19M-$10.34M-$5.09M-$7.09M-$1.39M-$2.69M-$2.29M
Financing cash flow$14.23M-$36.90M$824,000$3.40M-$21.10M$681.40M$1.28M$226,000
Depreciation & amortization$6.60M$6.50M$5.07M$4.29M$4.90M$6.40M$7.04M$9.07M
Stock-based compensation$18.50M$22.22M$15.87M$13.37M$13.65M$28.29M$14.69M$4.98M
Share buybacks$10.01M$21.36M$0$91,000$0$0$22,000$0

Free plan shows the latest 8 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.